SonicOne Study Shows Improved Wound Healing In Patients With Peripheral Vascular Disease

Misonix, Inc. (NasdaqGM: MSON), an international surgical device company that designs, manufactures and markets innovative therapeutic ultrasonic products for spine surgery, skull-based surgery, neurosurgery, wound debridement, cosmetic surgery, laparoscopic surgery and other surgical applications reported today that a SonicOne clinical paper was presented at the Canadian Association of Wound Care 20th Annual Conference in Toronto, Ontario held October 30 - November 2, 2014. The SonicOne is an innovative surgical device that allows clinicians to address the challenges chronic wounds present to them, the patient, and the health-care system. SonicOne establishes a new standard in wound debridement, an essential component in the wound healing process. Use of the SonicOne system provides controlled tissue removal, reduced healing times, minimal bleeding and a reduction of bioburden and biofilm.In an abstract entitled, "The Effect of Low Frequency 22.5kHz Contact Ultrasound-assisted Debridement (LFCUD) on Lower Extremity Wounds in a Vascular Surgery Clinic: A Pilot Study", Murphy, Houghton, Brandys and Rose concluded that LFCUD improved tissue quality and decreased Wound Surface Area in a complex patient population with peripheral vascular disease. These results achieved statistical significance."SonicOne was easy to use, comfortable for the patient and permitted grafted closure in a population often ineligible," said study lead Christine Murphy, a wound care nurse at The Ottawa Hospital in Ontario, Canada. "Our pilot study showed that LFCUD was a well-tolerated and convenient method of debridement because it could be administered by non-physician staff outside of the operating room and resulted in improved healing outcomes in the majority of cases involved."The pilot study has evolved into a randomized controlled clinical trial that is currently underway at The Ottawa Hospital's Wound Healing Centre. The trial has enrolled 46 of 82 patients to date and is scheduled to complete enrollment in the spring of 2015."These are very exciting findings as the peripheral vascular diseased patient population in this study represents some of the most challenging wound cases to effectively bring to healing. SonicOne ultrasonic wound debridement continues to be highly regarded as a safe and effective means to improve wound healing, even in the complex patient," said Michael A. McManus, Jr., President and Chief Executive Officer of Misonix.